The anti-asparagines antibodies correlate with l-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 48, Issue 5, 2007, Pages 931-936

  Zalewska Szewczyk, Beata ^a   Andrzejewski, Witalij ^a   Młynarski, Wojciech ^a   Jȩdrychowska Danska, Krystyna ^a   Witas, Henryk ^a   Bodalski, Jerzy ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Acute lymphoblastic leukemia; Allergy; Antibodies; Children; L Asparaginase

Indexed keywords

ASPARAGINASE; ASPARAGINASE ANTIBODY; ASPARAGINE; ENZYME ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLERGIC REACTION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER RISK; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SAMPLE SIZE;

ADOLESCENT; ANTIBODIES; ASPARAGINE; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34547444893     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701292049     Document Type: Article

References (17)

1. Broome, J. D. (1963) Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects and properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J Exp Med, 118, pp. 99-120.
2. Müller, H. J. and Boos, J. (1998) Use of L-asparaginase in childhood ALL. Critical Rev Oncol Hematol, 28, pp. 97-113.
3. Eden, O. B., Shaw, M. P., Lilleyman, J. S. and Richard, S. (1990) Non-randomized study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukemia. Med Ped Oncol, 18, pp. 497-502.
4. Nesbit, M., Chard, R. and Evans, A. (1979) Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol, 1, pp. 120-124.
5. Cheung, N. K., Chau, I. Y. and Coccia, P. F. (1986) Antibody response to Escherichia coli-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol, 19, pp. 400-408.
6. Asselin, B. L., Whitin, J. C., Coppola, D. J., Rupp, I. P., Sallan, S. E. and Cohen, H. J. (1993) Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol, 11, pp. 1780-1786.
7. Zalewska-Szewczyk, B., Andrzejewski, W. and Bodalski, J. (2004) Development of anti-asparaginase antibodies in childhood lymphoblastic leukemia. Pediatric Blood Cancer, 43, pp. 600-602.
8. Panosyan, E. H., Seibel, N. L., Martin-Aragon, S., Gaynon, P. S., Avramis, I. A. and Sather, H. (2004) Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia. J Pediatr Hematol Oncol, 26, pp. 217-226.
9. Wahn, V., Fabry, U., Korholz, D., Reinhardt, D., Jurgens, H. and Gobel, U. (1983) Modified pharmacokinetics of L-asparaginase from E. coli by formation of specific antibodies to -asparaginase of different immunoglobulin classes in children with acute lymphoblastic leukemia. Pediatr Pharmacol, 3, pp. 303-311.
10. Woo, M. H., Hak, L. J., Storm, M. C., Evans, W. E., Sandlund, J. T. and Rivera, G. K. (1998) Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia, 12, pp. 1527-1533.
11. Schrappe, M., Reiter, A., Zimmermann, M., Harbott, J., Ludwig, W. D. and Henze, G. (2000) Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 - 1995. Berlin-Frankfurt-Munster. Leukemia, 14, pp. 2205-2222.
12. Müller, H. J., Löning, L., Horn, A., Schwabe, D., Gunkel, M. and Schrappe, M. (2000) Pegylated asparaginase (Oncaspar™) in children with ALL: Drug monitoring in reinduction according to the ALL/ NHL-BFM 95 protocols. Br J Haematol, 110, pp. 379-384.
13. Killander, D., Dohlwitz, A. and Engstedt, L. (1976) Hypersensitive reactions and antibody formation during -asparaginase treatment of children and adults with acute leukemia. Cancer, 37, pp. 220-228.
14. Woo, M. H., Hak, L. J., Storm, M. C., Sandlund, J. T., Ribeiro, R. C. and Rivera, G. K. (2000) Hypersensivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol, 18, pp. 1525-1532.
15. Larson, R. A., Fretzin, M. H., Dodge, R. K. and Schiffer, C. A. (1998) Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia, 12, pp. 660-665.
16. Albertsen, B. K., Schrøder, H., Jakobsen, P. and Avramis, V. I. (2002) Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol, 38, pp. 310-316.
17. Klug-Albertsen, B., Schmiegelow, K., Schroder, H., Carlsen, N. T., Rosthoy, S. and Avramis, V. I. (2002) Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: A case-control study. Cancer Chemother Pharmacol, 50, pp. 117-120.